PRTA - Prothena Corporation plc
| Previous Close | 11.5000 |
| Open | 11.5500 |
| Bid | 11.3600 x 800 |
| Ask | 11.3700 x 2300 |
| Day's Range | 11.2500 - 12.1452 |
| 52 Week Range | 11.0500 - 70.0000 |
| Volume | 2,905,154 |
| Avg. Volume | 809,261 |
| Market Cap | 436.549M |
| Beta | 3.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0700 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 73.09 |
- PR Newswire•3 hours ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Prothena Corporation plc (PRTA)
NEW YORK , April 24, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Prothena Corporation plc ("Prothena" ...
- PR Newswire•4 hours ago
Prothena Shareholder Alert - PRTA Stock Drops Almost 70% - Kehoe Law Firm, P.C. Investigating
PHILADELPHIA , April 24, 2018 /PRNewswire/ -- Kehoe Law Firm, P.C. is conducting a securities investigation on behalf of investors of Prothena Corporation plc (NASDAQ: PRTA) to determine whether Prothena ...
- Market Exclusive•4 hours ago
Here’s What Just Happened With Prothena And Kamada
Prothena Corporation plc (NASDAQ:PRTA) is attracting a substantial amount of attention in the biotechnology space early this week on the back of news that the company has decided to discontinue one of its lead development programs. This is a major setback and, as might be expected, Prothena shares have taken a hit in line with […] The post Here’s What Just Happened With Prothena And Kamada appeared first on Market Exclusive.
- Financial Times•8 hours ago
[$$] Prothena plunge dents Woodford portfolio after 2017 drop
Neil Woodford’s Patient Capital Trust sustained a blow from Monday’s plunge in Prothena shares, the group revealed on Tuesday, while also disclosing a fall last year the value of its portfolio. Net asset value fell by 2 per cent over the 12 months to December and shares shed 7.2 per cent following losses among stocks like drugs company Circassia and Allied Mind, the trust said in its annual report. Patient Capital also on Tuesday said that the Prothena tumble had knocked the valuation of its holding in the group down by 68 per cent compared with the level it had calculated at the end of last year.
- Reuters•9 hours ago
Woodford-backed biotech Prothena plunges as key drug fails
Shares in Prothena (PRTA.O), a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial. As a result, Prothena is discontinuing development of the antibody-based medicine for the condition. The news is a win for short sellers who have targeted the stock but a fresh setback for Woodford, one of Britain's best-known fund managers.
- Financial Times•13 hours ago
[$$] Woodford’s Patient Capital Trust reports disappointing year
City fund manager Neil Woodford has reported falls in the share price and net asset value of his £626m investment trust, just one day after bad news on a drug development caused a sharp fall in the value ...
- Business Wire•16 hours ago
PROTHENA CORPORATION INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law Violations
Girard Gibbs LLP is investigating claims on behalf of investors of Prothena Corporation (PRTA) involving possible securities law violations. Specifically, our investigation focuses on whether Prothena issued materially misleading business information to the investing public or engaged in other unlawful business practices. To speak privately with an attorney regarding this class action lawsuit investigation, click here.
- PR Newswire•18 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prothena Corporation plc - PRTA
NEW YORK , April 23, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prothena Corporation plc ("Prothena" or the "Company") (NASDAQ: PRTA). Such ...
- American City Business Journals•20 hours ago
After headline drug flops in trials, Peninsula biotech sheds 70% of its value
The South San Francisco company halted development of a drug for a rare protein-misfolding condition that causes heart problems, resulting in a $534 million drop in market value.
- Investor's Business Daily•21 hours ago
Prothena Shares Tumble Nearly 70% After It Scraps Rare Disease Drug
Shares of Prothena crashed early Monday after it scrapped a drug that failed in a Phase 2 study and looked likely to flop in a late-stage test.
- Motley Fool•yesterday
Why Prothena Corporation plc Is Imploding Today
Shares plunge after the company announces that it is halting development of its lead pipeline candidate. Here's what investors need to know.
- MarketWatch•yesterday
Prothena shares plummet 60% on discontinued drug
Prothena Corp. PLC shares plummeted 60% in premarket trade Monday after the company said it is discontinuing development of AL amyloidosis therapy NEOD00, the most advanced therapy in its pipeline. The ...
- GlobeNewswire•yesterday
Prothena Discontinues Development of NEOD001 for AL Amyloidosis
Phase 2b PRONTO study did not meet its primary or secondary endpoints Phase 3 VITAL Amyloidosis Study being discontinued based on futility analysis Investor conference call and webcast today at 8:30 AM ...
- GlobeNewswire•yesterday
Prothena Discontinues Development of NEOD001 for AL Amyloidosis
Phase 2 b PRONTO study did not meet its primary or secondary endpoints Phase 3 VITAL Amyloidosis Study being discontinued based on futility analysis Investor conference call and webcast today at 8:30 AM ...
- Financial Times•2 days ago
[$$] Prothena goes splat
A pre-market update from Prothena, the Nasdaq-listed biotech which many had hoped had a treatment for amyloidosis in the works, had bad news to convey Monday: As a reminder, Woodford Investment Management ...
- GlobeNewswire•12 days ago
Consolidated Research: 2018 Summary Expectations for Insight Enterprises, Amphastar Pharmaceuticals, EMC Insurance Group, Prothena Corporation plc, Mizuho Financial Group, and Baytex Energy — Fundamental Analysis, Key Performance Indications
NEW YORK, April 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•15 days ago
Implied Volatility Surging for Prothena (PRTA) Stock Options
Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.
- Zacks•28 days ago
Acorda Files Parkinson's Drug Marketing Application in EU
Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.
- Market Exclusive•last month
Here’s Why Alder BioPharmaceuticals And Prothena Corporation Are Moving Today
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) has taken a hit during the early part of this week on the back of news that one of the company’s leading executives, Randall C. Schatzman, who serves as the current CEO of Alder, will be stepping down to make way for Paul B. Cleveland, a member of the Board of […] The post Here’s Why Alder BioPharmaceuticals And Prothena Corporation Are Moving Today appeared first on Market Exclusive.
- Motley Fool•last month
Why Prothena Corp plc Shot 14.4% Higher Today
The company's landed a new collaboration partner and a new investor.
- Investor's Business Daily•last month
Prothena Rockets On Celgene Tie-Up In Neurological Diseases
Prothena jumped to a seven-week high Wednesday on a $150 million collaboration deal with Celgene.
- Zacks•last month
Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
- Zacks•last month
Prothena Rallies on Multi-Year Collaboration With Celgene
Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.
- Investopedia•last month
Prothena Stock Skyrockets on Celgene Collab
Prothena announced a new collaboration with Celgene in which the latter is giving it an upfront $100 million and investing $50 million.
- Investor's Business Daily•last month
This Biotech Stock Rocketed On A $150 Million Deal With Celgene
Prothena jumped by doubt digits late Tuesday on a $150 million deal with Celgene to develop treatments for neurodegenerative diseases.
